学会発表(国際)

  • Kumamaru H, Takeuchi Y, Kohsaka S, Matsui H, Yasunaga H, Miyata H. Comparative effectiveness of First-line SGLT2 inhibitor use on heart failure hospitalization among patients with type 2 diabetes mellitus; A target trial emulation (Poster presentation). 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 2022 Aug, Copenhagen/Online.
  • Takeuchi Y, Iwagami M, Ono S, Yasunaga H. Serious adverse effects after COVID-19 vaccination in Japan: Analysis using administrative claims data linked with vaccination registry. 14th Asian Conference on Pharmacoepidemiology. 2022 Oct, Tainan/Online.
  • Takada M, Shigehira Saji, Takayuki Ueno, Norikazu Masuda, Hiroshi Ishiguro, Takanori Ishida, Toshiaki Saeki, Shigeru Imoto, Shinji Ohno, Yoshinori Ito, Hiroji Iwata, Tomoharu Sugie, Kenjiro Aogi, Hirofumi Mukai, Shin Takayama, Nobuaki Sato, Yuichiro Kai, Masahiro Kitada, Yutaka Matsuyama, Masakazu Toi. Adjuvant S-1 plus endocrine therapy for estrogen receptor-positive, HER2-negative, primary breast cancer: update overall survival analysis from the POTENT trial. SABCS2022. 45th San Antonio Breast Cancer Symposium. 12/6/2022 - 12/10/2022.
  • Yoshikuni Kawaguchi, Ryuichi Kita, Toru Kimura, Tadatoshi Takayama, Namiki Izumi, Masatoshi Kudo, Shuichi Kaneko, Naoki Yamanaka, Masahumi Inomata, Mitsuo Shimada, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo, Kiyoshi Hasegawa. Medical Expenditures and Treatment Efficacy of Patients who had Initial Hepatocellular Carcinoma and Underwent Surgery or Radiofrequency Ablation: Accompanying Research of the SURF Trial. ESMO2022.
  • Tatsuya Yamashita, Yoshikuni Kawaguchi, Shuichi Kaneko, Tadatoshi Takayama, Namiki Izumi, Naoki Yamanaka, Masatoshi Kudo, Mitsuo Shimada, Masafumi Inomata, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo, Kiyoshi Hasegawa. A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival. 2022 ASCO Annual Meeting (June 3 - June 7, 2022).

TOP